Pharmaceutical

Scorpion inks deal with Pierre Fabre for next-gen EGFR ...

The company announced the signing of a multimillion-dollar deal, with IND submis...

1 in 6 people experience infertility worldwide, accordi...

The WHO recommends that countries offer universal health coverage of fertility t...

Hospitals pledge to protect patient privacy. Almost all...

“One cannot really access a hospital website in this country without being expos...

EC grants marketing authorisation for Sandoz’s biosimil...

Sandoz’s Hyrimoz received approval for all the indications that are covered by t...

Ablaze Pharmaceuticals to develop drug candidate for li...

Liver cancer is considered to be the third most common cause of cancer death and...

Tango Therapeutics’ IND application for TNG260 receives...

The phase 1/2 clinical study will test the safety, pharmacokinetics, pharmacodyn...

BioNTech and DualityBio team up to develop ADC therapeu...

Once developed, the ADCs will join BioNTech’s existing portfolio of oncology pro...

Innate Pharma and Takeda sign licence deal to develop A...

Innate will receive royalties on possible net sales of any commercial product to...

HUTCHMED concludes FDA rolling submission for colorecta...

The NDA submission is supported by data from the Phase III FRESCO and FRESCO-2 t...

Latest WHO Covid-19 vaccine guidance may decrease futur...

SAGE also updated its guidance on bivalent Covid-19 vaccines, now recommending t...

EMA’s CHMP recommends Bristol Myers Squibb’s Breyanzi a...

The CHMP’s positive opinion was based on the data obtained from the pivotal Phas...

Eisai and National Cancer Center partner for tazemetost...

Eisai will be responsible for providing tazemetostat to the National Cancer Cent...

STAT+: FTC tells Illumina to divest Grail, boosting Ica...

The U.S. Federal Trade Commission on Monday ordered DNA sequencing giant Illumin...

STAT+: A young boy’s nightmare diagnosis, and the $3 mi...

Bluebird's Skysona gene therapy is expected to save the lives of patients with t...

STAT+: Pharmalittle: FDA slams company recalling eye dr...

Good morning, everyone, and welcome to another working week. We hope the weekend...

STAT+: Vertex, CRISPR Therapeutics inch ahead of rival ...

Vertex Pharmaceuticals and its partner CRISPR Therapeutics said they had met the...